CRISPR Therapeutics(us:CRSP)
33.14
-2.62%
Updated on 2025-04-02
Open:33.99
Close:33.14
High:34.93
Low:33.01
Prev Close:34.03
Volume:2.18M
Turnover:73.19M
Turnover Ratio:2.54%
Shares:85.77M
MarketCap:2.84B
| Date | Total | Total Shares | Total Ratio | New | Increased | Decreased |
|---|---|---|---|---|---|---|
| 2024-06-30 | 12 | 25352 | 0.03% | 3 | 4 | 1 |
| 2024-03-31 | 524 | 58484639 | 68.94% | 71 | 155 | 191 |
| 2023-12-31 | 510 | 55480727 | 69.31% | 118 | 134 | 168 |
| 2023-09-30 | 449 | 54199539 | 68.24% | 43 | 151 | 152 |
| 2023-06-30 | 431 | 54091997 | 68.15% | 64 | 95 | 156 |
| 2023-03-31 | 422 | 55466000 | 70.33% | 45 | 98 | 173 |
| 2022-12-31 | 469 | 55492957 | 70.68% | 53 | 118 | 198 |
| 2022-09-30 | 472 | 55990706 | 71.55% | 52 | 122 | 167 |
| date | orgName | total | ratio | changeShares | changeRatio |
|---|---|---|---|---|---|
| 2024-06-30 | Capital International Investors | 7865253 | 9.25% | 28179 | 0.36% |
| 2024-06-30 | Ark Investment Management Llc | 7778536 | 9.15% | -378492 | -4.64% |
| 2024-06-30 | Nikko Asset Management Americas, Inc. | 3151514 | 3.71% | -117271 | -3.59% |
| 2024-06-30 | Sumitomo Mitsui Trust Holdings, Inc. | 3151514 | 3.71% | -117271 | -3.59% |
| 2024-06-30 | Blackrock Inc. | 2777784 | 3.27% | 231423 | 9.09% |
| 2024-06-30 | T. Rowe Price Investment Management, Inc. | 2730652 | 3.21% | 26321 | 0.97% |
| 2024-06-30 | State Street Corp | 2393684 | 2.81% | 898476 | 60.09% |
| 2024-06-30 | Fmr Llc | 2353091 | 2.77% | 113408 | 5.06% |
| 2024-06-30 | Vanguard Group Inc | 1748513 | 2.06% | 111714 | 6.83% |
| 2024-06-30 | Nea Management Company, Llc | 1587854 | 1.87% | 0 |
About
CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.
Address:Baarerstrasse 14
Website:http://www.crisprtx.com
Market Movers